The TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT; SKB264; MK-2870) yielded superior progression-free survival (PFS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic…
Sac-TMT Improves PFS in HR+/HER2– Metastatic Breast Cancer | Targeted Oncology
